BostonGene
The AI engine Fit Assessment
BetaBostonGene Corporation develops advanced biomedical software that utilizes AI for personalized therapy decision-making in cancer treatment, focusing on individual patient profiles and tumor characteristics. Their solutions include comprehensive molecular and immune profiling to optimize treatment options for patients.
Blurb
HQ Location
Founded
Employees
Total funding raised
Last Funding Event
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
- Drug Repurposing
Developer of a biomedical software designed for advanced patient analysis and personalized therapy. The company's software offers an artificial intelligence-powered molecular genetic and immune profiling platform to decode cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend effective treatments, enabling clinicians to get precise, clinically validated insights that drive precision medicine and advance oncology research.